Metrics as of 10/17/2026, 08:11 AM (Berlin time), refresh in progress.
Haemonetics Stock
Haemonetics Corporation
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Christopher A. Simon
- Employees
- 3,009
- Market cap
- $5.4 B
- IPO
- 10/05/1991
Haemonetics Corporation is a healthcare enterprise based in Boston, US, dedicated to providing medical products and comprehensive solutions. Founded in 1971, the company distributes its products through direct sales teams, independent distributors, and sales representatives. The business is structured into three main…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Haemonetics stock: price history
1D
-2.5%
1W
-0.3%
1M
+11.3%
6M
+92.0%
YTD
+47.6%
1Y
+137.7%
2Y
+56.5%
5Y
+69.2%
10Y
+246.4%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~159% stronger price swings than usual
Haemonetics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
2 more assignments (Enabler/Second row) Pro-only.
Haemonetics Corporation is a specialized medical technology company that provides solutions for plasma, blood centers, and hospitals. The business model encompasses the sale of hardware, such as apheresis devices and hemostasis analysis systems, as well as software solutions for blood supply management and clinical decision-making. A substantial portion of revenue is generated through consumables associated with the deployed devices. The company leverages an integrated model of hardware, software, and disposables to optimize clinical workflows and achieve long-term customer retention in specialized medical segments.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Haemonetics
Analyst assessment of Haemonetics
PRICE TARGET LOW
US$119.00
CONSENSUS
US$130.80
MEDIAN
US$130.00
PRICE TARGET HIGH
US$140.00
0
STRONG BUY
12
BUY
9
HOLD
0
SELL
0
STRONG SELL
21
TOTAL · Buy
As of: 09/10/2026
Haemonetics stock metrics
P/E
57.42
P/B
6.41
EV/EBITDA
24.24
RETURN ON EQUITY
3.9%
NET MARGIN
9.7%
DEBT/EQUITY
1.4
DIVIDEND YIELD
0.0%
AS OF
27/06/2026
Free float & liquidity
FREE FLOAT
98.7%
FLOAT SHARES
44,886,936
AVG. DAILY VOLUME (30D)
681,044
Insider transactions (SEC)
ABERNATHY ROBERT E
Bryant Diane M
COYLE MICHAEL J
Johnson Lloyd Emerson
KROLL MARK W
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.5%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Haemonetics stock
What does Haemonetics do?
Haemonetics Corporation is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Christopher A. Simon, the company employs around 3,009 people.
The IPO was on 10/05/1991; the stock trades on NYSE under the ticker HAE.
What do analysts say about Haemonetics stock?
21 analysts rate the stock, the consensus is Buy (as of 09/10/2026).
The average price target is US$130.80, ranging from US$119.00 to US$140.00, with a median of US$130.00.
This is an external assessment, not a statement by Market Jury.
When does Haemonetics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 159% stronger than usual.
Does Haemonetics pay a dividend?
No, Haemonetics currently does not pay a dividend.
Which stocks are comparable to Haemonetics?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Haemonetics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Haemonetics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.